Hero Image

Evidence-Based 2026 Migraine Care: Neuromodulation & CGRP

From neuromodulation wearables to targeted CGRP blockers, 2026 is shaping up to be a strong year for migraine care.

In this guide, we’ll break down evidence-backed options you can actually access now, how they work, and smart ways to combine them for better control.

FDA-cleared neuromodulation devices (drug-free relief)

Non‑drug neuromodulation tools deliver gentle electrical or magnetic stimulation to pain pathways involved in migraine. Many are prescribed today and can be used at home for either prevention, acute relief, or both.

They’re popular among people who can’t tolerate medication side effects, are planning pregnancy, or simply want to add a non‑pharmacologic layer to their plan. Most devices have short session times (20–45 minutes) and are designed to be used at the first sign of an attack or daily for prevention.

As with any therapy, effectiveness varies; some patients respond quickly while others need several weeks of consistent use. Work with your clinician to choose a device that matches your attack pattern, insurance coverage, and lifestyle.

Common wearable options

  • Cefaly – External trigeminal nerve stimulation; used daily for prevention and during attacks.
  • Nerivio – Remote electrical neuromodulation armband; worn during attacks for acute relief.
  • gammaCore (non‑invasive vagus nerve stimulator) – For acute treatment and, in some cases, prevention.
  • Relivion MG – Dual‑channel stimulation targeting trigeminal and occipital nerves.

Why patients choose neuromodulation

  • Drug‑free and non‑sedating
  • Can be combined with prescription medications
  • Often fewer systemic side effects
  • Practical for people sensitive to pharmaceuticals

Bottom line: these devices are real, accessible tools many patients are using now and into 2026.

CGRP inhibitors for prevention and acute treatment

CGRP‑targeting medicines have transformed migraine care over the last few years by going after a key pain pathway. They’re available as injectables for prevention and as oral “gepants” for acute treatment, with some options serving both roles.

Preventive CGRP monoclonal antibodies

  • Aimovig (erenumab)
  • Ajovy (fremanezumab)
  • Emgality (galcanezumab)
  • Vyepti (eptinezumab – IV infusion)

Acute CGRP receptor blockers (“gepants”)

  • Ubrelvy (ubrogepant) – acute
  • Nurtec ODT (rimegepant) – acute and preventive
  • Qulipta (atogepant) – preventive

What makes CGRP therapies appealing?

  • Targeted mechanism with generally fewer side effects than many older drugs
  • Flexible dosing: daily pills, monthly/quarterly injections, or quarterly infusions
  • Helpful for people who don’t respond to or can’t take triptans

Discuss insurance requirements and prior authorizations with your provider, as coverage can vary.

Traditional migraine medications still matter

Even with newer options, tried‑and‑true medications remain effective, accessible, and budget‑friendly. For many, they’re first‑line choices or key parts of a layered plan.

Acute treatments

  • Triptans (sumatriptan, rizatriptan, eletriptan, and others)
  • NSAIDs (ibuprofen, naproxen)
  • Dihydroergotamine (DHE) – nasal spray or injection
  • Combination therapy – for example, sumatriptan/naproxen

Preventive medications

  • Beta blockers (propranolol, metoprolol)
  • Anticonvulsants (topiramate, valproate)
  • Antidepressants (amitriptyline, venlafaxine)
  • Blood pressure agents (candesartan)

Choice depends on your health history and comorbidities (for example, beta blockers may be useful if you also have hypertension or anxiety). Your clinician can help tailor a plan and manage side effects.

Botox (onabotulinumtoxinA) for chronic migraine

Botox is FDA‑approved for chronic migraine, defined as 15 or more headache days per month. It’s given by a trained provider every 12 weeks using a standardized injection pattern.

  • Can reduce monthly headache days and intensity over time
  • Useful for those who haven’t responded to multiple oral preventives
  • May help curb medication‑overuse headaches

Many patients see meaningful benefit after the second treatment cycle. If you’re at or above the 15‑day threshold, ask about eligibility and coverage.

Behavioral and lifestyle therapies (clinically proven)

Mind‑body approaches can meaningfully reduce attack frequency and improve coping—especially when paired with medication or devices.

Evidence‑based options

  • Cognitive Behavioral Therapy (CBT) – builds skills to manage pain, stress, and triggers.
  • Biofeedback – trains control over muscle tension and autonomic responses.
  • Mindfulness‑based stress reduction (MBSR) – supports attention, acceptance, and stress resilience.
  • Regular aerobic exercise – even 3–5 sessions weekly can decrease frequency for many people.
  • Sleep regulation – consistent bed/wake times and wind‑down routines reduce variability that can trigger attacks.

Start small: pick one practice you can sustain for the next 4–6 weeks, track your results, then layer in the next habit.

Digital and app‑based migraine management tools

Clinically vetted apps make it easier to log symptoms, spot patterns, and share clean reports with your care team. Better data often leads to smarter, faster adjustments to your plan.

Popular, evidence‑informed apps

  • Migraine Buddy – robust tracking and analytics
  • N1‑Headache – helps identify individualized triggers
  • Mindfulness apps (e.g., Happify) – supportive alongside therapy
  • Companion apps from CGRP manufacturers – reminders, dosing logs, and response tracking

Pro tip: log consistently for at least a month to reveal patterns in triggers, timing, and responses.

Supplements with clinical support

Several supplements have enough evidence to consider as add‑ons. Always discuss dosing and interactions with your clinician, especially if you’re pregnant, planning pregnancy, or on other medications.

  • Magnesium oxide – commonly 400–600 mg daily (watch for GI side effects)
  • Riboflavin (vitamin B2) – often 400 mg daily
  • CoQ10 – typically 100–300 mg daily
  • Feverfew – consider only with guidance; product quality and interactions vary

Supplements aren’t replacements for medical therapy, but they can be helpful additions to a comprehensive plan.

What you can use in 2026: quick checklist

  • Neuromodulation devices: Cefaly, Nerivio, gammaCore, Relivion
  • CGRP inhibitors: Aimovig, Ajovy, Emgality, Vyepti, Ubrelvy, Nurtec ODT, Qulipta
  • Botox for chronic migraine
  • Traditional medications: triptans, NSAIDs, anticonvulsants, beta blockers, antidepressants
  • Behavioral therapies: CBT, biofeedback, mindfulness, exercise, sleep regulation
  • Clinically validated migraine apps
  • Evidence‑based supplements

These are accessible, proven migraine treatments available as of late 2025—and reliable choices going into 2026. Work with your healthcare provider to build a personalized, layered plan that fits your goals, lifestyle, and budget.